Eurofins Scientific SE
ERF
Rangering i aksjer
#1379
Eurofins Scientific SE, together with its subsidiaries, provides various... Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
Aksjekurs
$93.33
Sist synkronisert: 2026-10-20
Markedsverdi
$16.20B
Endring (1 dag)
-0.33%
Endring (1 år)
28.73%
Land
LU
Handel Eurofins Scientific SE (ERF)
Kategori
Healthcare
P/E-forhold for Eurofins Scientific SE (ERF)
P/E-forhold per October 2026 TTM: 25.95
Ifølge Eurofins Scientific SE sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 25.95. Ved slutten av 2024 hadde selskapet en P/E på 23.13.
P/E-forholdshistorikk for Eurofins Scientific SE fra 2002 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 25.95 | 9.74% |
| 2025 | 23.65 | 2.25% |
| 2024 | 23.13 | -36.93% |
| 2023 | 36.67 | 73.31% |
| 2022 | 21.16 | -20.54% |
| 2021 | 26.62 | 12.38% |
| 2020 | 23.69 | -47.43% |
| 2019 | 45.07 | 74.87% |
| 2018 | 25.77 | -36.00% |
| 2017 | 40.27 | 8.19% |
| 2016 | 37.22 | -33.98% |
| 2015 | 56.37 | 38.99% |
| 2014 | 40.56 | -0.63% |
| 2013 | 40.82 | 50.69% |
| 2012 | 27.09 | 86.10% |
| 2011 | 14.55 | -55.58% |
| 2010 | 32.76 | -168.24% |
| 2009 | -48.01 | -270.41% |
| 2008 | 28.17 | -55.04% |
| 2007 | 62.67 | 45.55% |
| 2006 | 43.06 | 3.50% |
| 2005 | 41.60 | 44.58% |
| 2004 | 28.77 | -65.77% |
| 2003 | 84.05 | -92.15% |
| 2002 | 1.07K | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 36.15 | 39.31% |
US
|
|
| 39.77 | 53.25% |
US
|
|
| -290.26 | -1,218.38% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 31.72% |
US
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.